Technical Analysis for AKCA - Akcea Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 22.85 -1.97% -0.46
AKCA closed down 1.97 percent on Monday, October 15, 2018, on 88 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Nov 5

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical AKCA trend table...

Date Alert Name Type % Chg
Oct 15 Calm After Storm Range Contraction 0.00%
Oct 15 Narrow Range Bar Range Contraction 0.00%
Oct 15 NR7 Range Contraction 0.00%
Oct 15 Wide Bands Range Expansion 0.00%
Oct 15 Down 3 Days in a Row Weakness 0.00%
Oct 15 Down 4 Days in a Row Weakness 0.00%
Oct 15 Oversold Stochastic Weakness 0.00%
Oct 12 Fell Below 200 DMA Bearish -1.97%
Oct 12 Wide Bands Range Expansion -1.97%
Oct 12 Down 3 Days in a Row Weakness -1.97%

Older signals for AKCA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).
Is AKCA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 40.75
52 Week Low 15.2
Average Volume 363,841
200-Day Moving Average 25.377
50-Day Moving Average 30.4556
20-Day Moving Average 30.072
10-Day Moving Average 28.275
Average True Range 2.7937
ADX 26.76
+DI 15.9212
-DI 32.5901
Chandelier Exit (Long, 3 ATRs ) 29.3489
Chandelier Exit (Short, 3 ATRs ) 30.9511
Upper Bollinger Band 37.8597
Lower Bollinger Band 22.2843
Percent B (%b) 0.04
BandWidth 51.793695
MACD Line -1.1652
MACD Signal Line -0.1246
MACD Histogram -1.0406
Fundamentals Value
Market Cap 1.46 Billion
Num Shares 63.9 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -12.09
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.58
Resistance 3 (R3) 24.67 24.20 24.29
Resistance 2 (R2) 24.20 23.76 24.15 24.19
Resistance 1 (R1) 23.52 23.49 23.29 23.43 24.10
Pivot Point 23.05 23.05 22.93 23.00 23.05
Support 1 (S1) 22.37 22.61 22.14 22.28 21.60
Support 2 (S2) 21.90 22.34 21.85 21.51
Support 3 (S3) 21.22 21.90 21.41
Support 4 (S4) 21.13